StockNews.AI
NVO
StockNews.AI
104 days

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

1. Operating profit increased 22% to DKK 38.8 billion. 2. Obesity care sales surged 67%, boosted overall sales. 3. CagriSema trial showed 15.7% weight loss, FDA filing expected in 2026. 4. Sales growth outlook adjusted down due to slower GLP-1 treatment penetration. 5. Global obesity market potential remains vast with only few on treatment.

Earnings
+1.9%Current Return
VS
+0.42%S&P 500
$66.2905/07 01:35 AM EDTEvent Start
$67.5505/08 08:06 AM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

Strong sales growth in obesity care suggests robust future revenue, despite some short-term issues.

How important is it?

Positive financial performance and product advancements are crucial for NVO's market confidence.

Why Long Term?

Regulatory advancements and ongoing R&D in obesity care indicate sustained growth potential.

Related Companies

NVOSNYPFELLYAZN
7 May 2025 -  Financial report for the period 1 January 2025 to 31 March 2025                                                                                                                                                                               Operating profit increased by 22% in Danish kroner and by 20% at constant exchange rates (CER) to DKK 38.8 billion.Sales in US Operations increased by 20% in Danish kroner (17% at CER). Sales in International Operations increased by 18% in Danish kroner (19% at CER).Sales within Diabetes and Obesity care increased by 21% in Danish kroner to DKK 73.5 billion (19% at CER), mainly driven by Obesity care growth of 67% in Danish kroner to DKK 18.4 billion (65% at CER) and GLP-1 diabetes sales growing 13% in Danish kroner (11% at CER) and. Rare disease sales increased by 5% measured in Danish kroner (3% at CER).Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.Also within R&D, oral semaglutide 25 mg in obesity was submitted for regulatory review to the US FDA. In addition, once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US, and granted priority review in the US. For the 2025 outlook, sales growth is now expected to be 13-21% at CER, and operating profit growth is now expected to be 16-24% at CER. Sales and operating profit growth reported in Danish kroner is now expected to be 3 and 5 percentage points lower than at CER, respectively. The updated sales outlook reflects lower-than-planned penetration of branded GLP-1 treatments in the US, impacted by compounded GLP-1s. Novo Nordisk is focused on preventing unlawful compounding and further expanding access in the US. With around 1 billion people living with obesity globally and only few million on treatment, Novo Nordisk continues the global roll-out of Wegovy®. PROFIT AND LOSSQ1 2025Q1 2024Growthas reportedGrowthat CER*DKK million    Net sales78,08765,349        19%        18%Operating profit38,79131,846        22%        20%     Net profit29,03425,407        14%        N/ADiluted earnings per share (in DKK)6.535.68        15%        N/A* CER: Constant exchange rates (average 2024).     Lars Fruergaard Jørgensen, president and CEO: "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US. We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments. Within R&D, we are pleased to have completed the last pivotal trial for our next-generation obesity treatment, CagriSema, and to have filed for US approval of oral semaglutide 25 mg, with the potential to be the first oral GLP-1 treatment for obesity." On 7 May 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown+45 3079 9289abmo@novonordisk.comLiz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com   Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.comSina Meyer+45 3079 6656azey@novonordisk.comIda Schaap Melvold+45 3077 5649idmg@novonordisk.comFrederik Taylor Pitter (US)+1 609 613 0568fptr@novonordisk.comMax Ung+45 3077 6414mxun@novonordisk.com  Company announcement No 14 / 2025 CA250507-Q1-2025

Related News